ASCO GI 2025: Everolimus and Lanreotide Combo as a Breakthrough for Gastroenteropancreatic Neuroendocrine Tumors
The combination of everolimus, an mTOR inhibitor, and lanreotide, a hormone-blocking agent, has shown significant promise in extending progression-free survival (PFS) and improving objective response rates (ORR) for patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This first-line treatment strategy was particularly beneficial for patients with high-risk prognostic factors, showing better outcomes compared to everolimus alone.
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen